Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer

Inclusion Criteria:

* Patients must have histologically and cytologically confirmed metastatic (Stage IV), locally advanced unresectable (stage III), or locally recurrent pancreatic adenocarcinoma, with or without prior chemotherapy for their cancer.
* Eastern Cooperative Oncology Group (ECOG) performance status being 0-2.
* Expected survival \>3 months.
* Patients 18 years of age and older of both genders.
* Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device \[IUD\], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 2 weeks prior to treatment initiation.
* Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists.
* At least 2 weeks must have elapsed from any prior surgery or hormonal therapy.
* Laboratory values ≤2 weeks must be:

  * Adequate hematologic
  * Adequate hepatic function
  * Adequate renal function
* No evidence of active infection and no serious infections within the past month.
* Mentally competent, able to understand and willing to sign the informed consent form.

Exclusion Criteria:

* Patients under the age of 18.
* Locally advanced resectable disease from pancreatic cancer
* Previous radiotherapy for cerebral metastases, central nervous system (CNS) or epidural tumor.
* Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any non-cancer indication within the past 4 weeks.
* Patients with any active uncontrolled bleeding, or a bleeding diathesis.
* Pregnant women, or women of child-bearing potential not using reliable means of contraception.
* Lactating females.
* Fertile men unwilling to practice contraceptive methods during the study period.
* Life expectancy less than 3 months.
* Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.
* Unwilling or unable to follow protocol requirements.
* Active heart disease including but not limited to symptomatic congestive heart failure, symptomatic coronary artery disease, symptomatic angina pectoris, symptomatic myocardial infarction, or symptomatic congestive heart failure.
* Patients with a history of myocardial infarction that is \< 3 months prior to registration.
* Patients with any amount of clinically significant pericardial effusion.
* Evidence of active serious infection.
* Patients with known HIV infection.
* Requirement for immediate palliative treatment of any kind including surgery and radiation.
* Patients that have received a chemotherapy regimen requiring stem cell support in the previous 6 months.
* Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of the patient.